Chronic lung allograft dysfunction phenotypes and treatment
Evidence level: narrative review; abstract-only
A 2017 review of the BOS and RAS phenotypes of CLAD, their features and risk factors, and treatment strategies that have been tried.
As of . Primary source: Publisher record via DOI.
Summary
This review describes the two CLAD phenotypes, BOS and restrictive allograft syndrome or restrictive CLAD. According to the abstract, BOS is characterised by obstructive lung function, air trapping on CT and obliterative bronchiolitis on histopathology, while RAS or rCLAD shows restrictive lung function, persistent pleuroparenchymal infiltrates on CT and pleuroparenchymal fibroelastosis on biopsy. The abstract reports survival after diagnosis of 6 to 18 months for RAS or rCLAD, compared with 3 to 5 years for BOS. The review also covers risk factors and an overview of treatment strategies that have been tried with some success, and notes that adequate phenotyping remains difficult. The specific treatments were not read. This summary describes the literature and is not medical advice.
Details
- doi
- 10.21037/jtd.2017.07.81
- pmid
- 28932572
- authors
- Verleden SE, Vos R, Vanaudenaerde BM, Verleden GM
- journal
- Journal of Thoracic Disease
- year
- 2017
- volume
- 9
- issue
- 8
- pages
- 2650-2659
Sources and links
- Publisher record via DOI (primary)
- PubMed 28932572
Related
Links from this record
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- author affiliations
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.